• Je něco špatně v tomto záznamu ?

Novel sulphur-containing imatinib metabolites found by untargeted LC-HRMS analysis

I. Vrobel, D. Friedecký, E. Faber, L. Najdekr, K. Mičová, R. Karlíková, T. Adam,

. 2017 ; 104 (-) : 335-343. [pub] 20170420

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18025074

Untargeted metabolite profiling using high-resolution mass spectrometry coupled with liquid chromatography (LC-HRMS), followed by data analysis with the Compound Discoverer 2.0™ software, was used to study the metabolism of imatinib in humans with chronic myeloid leukemia. Plasma samples from control (drug-free) and patient (treated with imatinib) groups were analyzed in full-scan mode and the unknown ions occurring only in the patient group were then, as potential imatinib metabolites, subjected to multi-stage fragmentation in order to elucidate their structure. The application of an untargeted approach, as described in this study, enabled the detection of 24 novel structurally unexpected metabolites. Several sulphur-containing compounds, probably originating after the reaction of reactive intermediates of imatinib with endogenous glutathione, were found and annotated as cysteine and cystine adducts. In the proposed mechanism, the cysteine adducts were formed after the rearrangement of piperazine moiety to imidazoline. On the contrary, in vivo S-N exchange occurred in the case of the cystine adducts. In addition, N-O exchange was observed in the collision cell in the course of the fragmentation of the cystine adducts. The presence of sulphur in the cysteine and cystine conjugates was proved by means of ultra-high resolution measurements using Orbitrap Elite. The detection of metabolites derived from glutathione might improve knowledge about the disposition of imatinib towards bioactivation and help to improve understanding of the mechanism of its hepatotoxicity or nephrotoxicity in humans.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025074
003      
CZ-PrNML
005      
20180713114223.0
007      
ta
008      
180709s2017 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejps.2017.04.014 $2 doi
035    __
$a (PubMed)28433749
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Vrobel, Ivo $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00 Olomouc, Czech Republic; Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
245    10
$a Novel sulphur-containing imatinib metabolites found by untargeted LC-HRMS analysis / $c I. Vrobel, D. Friedecký, E. Faber, L. Najdekr, K. Mičová, R. Karlíková, T. Adam,
520    9_
$a Untargeted metabolite profiling using high-resolution mass spectrometry coupled with liquid chromatography (LC-HRMS), followed by data analysis with the Compound Discoverer 2.0™ software, was used to study the metabolism of imatinib in humans with chronic myeloid leukemia. Plasma samples from control (drug-free) and patient (treated with imatinib) groups were analyzed in full-scan mode and the unknown ions occurring only in the patient group were then, as potential imatinib metabolites, subjected to multi-stage fragmentation in order to elucidate their structure. The application of an untargeted approach, as described in this study, enabled the detection of 24 novel structurally unexpected metabolites. Several sulphur-containing compounds, probably originating after the reaction of reactive intermediates of imatinib with endogenous glutathione, were found and annotated as cysteine and cystine adducts. In the proposed mechanism, the cysteine adducts were formed after the rearrangement of piperazine moiety to imidazoline. On the contrary, in vivo S-N exchange occurred in the case of the cystine adducts. In addition, N-O exchange was observed in the collision cell in the course of the fragmentation of the cystine adducts. The presence of sulphur in the cysteine and cystine conjugates was proved by means of ultra-high resolution measurements using Orbitrap Elite. The detection of metabolites derived from glutathione might improve knowledge about the disposition of imatinib towards bioactivation and help to improve understanding of the mechanism of its hepatotoxicity or nephrotoxicity in humans.
650    _2
$a antitumorózní látky $x krev $x metabolismus $x moč $7 D000970
650    _2
$a chromatografie kapalinová $7 D002853
650    _2
$a cystein $x metabolismus $7 D003545
650    _2
$a cystin $x metabolismus $7 D003553
650    _2
$a lidé $7 D006801
650    _2
$a imatinib mesylát $x krev $x metabolismus $x moč $7 D000068877
650    _2
$a inhibitory proteinkinas $x krev $x metabolismus $x moč $7 D047428
650    _2
$a síra $x krev $x metabolismus $x moč $7 D013455
650    _2
$a tandemová hmotnostní spektrometrie $x metody $7 D053719
655    _2
$a časopisecké články $7 D016428
700    1_
$a Friedecký, David $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00 Olomouc, Czech Republic; Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic; Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic. Electronic address: david.friedecky@upol.cz.
700    1_
$a Faber, Edgar $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
700    1_
$a Najdekr, Lukáš $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00 Olomouc, Czech Republic; Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
700    1_
$a Mičová, Kateřina $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00 Olomouc, Czech Republic; Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
700    1_
$a Karlíková, Radana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00 Olomouc, Czech Republic; Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
700    1_
$a Adam, Tomáš $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00 Olomouc, Czech Republic; Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic; Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
773    0_
$w MED00001639 $t European journal of pharmaceutical sciences official journal of the European Federation for Pharmaceutical Sciences $x 1879-0720 $g Roč. 104, č. - (2017), s. 335-343
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28433749 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180713114517 $b ABA008
999    __
$a ok $b bmc $g 1317205 $s 1021995
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 104 $c - $d 335-343 $e 20170420 $i 1879-0720 $m European journal of pharmaceutical sciences $n Eur. j. pharm. sci. (Print) $x MED00001639
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace